News
OCUL
11.12
+0.36%
0.04
Weekly Report: what happened at OCUL last week (0630-0704)?
Weekly Report · 4d ago
Weekly Report: what happened at OCUL last week (0623-0627)?
Weekly Report · 06/30 10:59
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Barchart · 06/26 12:54
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
Benzinga · 06/24 16:30
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Ocular Therapeutix (OCUL) and Vertex Pharmaceuticals (VRTX)
TipRanks · 06/23 13:10
Weekly Report: what happened at OCUL last week (0616-0620)?
Weekly Report · 06/23 10:52
Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade)
Seeking Alpha · 06/16 19:37
Weekly Report: what happened at OCUL last week (0609-0613)?
Weekly Report · 06/16 10:58
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Seeking Alpha · 06/12 15:03
Ocular Therapeutix Approves Key Amendments at Annual Meeting
TipRanks · 06/11 20:43
Weekly Report: what happened at OCUL last week (0602-0606)?
Weekly Report · 06/09 10:59
Ocular Therapeutix CMO Makes a Strategic Stock Move
TipRanks · 06/04 02:02
Weekly Report: what happened at OCUL last week (0526-0530)?
Weekly Report · 06/02 11:07
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews
Benzinga · 05/29 19:02
Ocular Therapeutix Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 05/29 16:25
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $15 Price Target
Benzinga · 05/29 16:15
Ocular Therapeutix’s Promising Clinical Trials and Strategic Advancements Justify Buy Rating
TipRanks · 05/29 15:45
Interesting OCUL Put And Call Options For April 2026
NASDAQ · 05/29 14:59
Scotiabank Keeps Their Buy Rating on Ocular Therapeutix (OCUL)
TipRanks · 05/29 11:46
Clear Street Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
TipRanks · 05/29 07:55
More
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.